Pull to refresh
Logo
Daily Brief
Following Why
Takeda’s once–daily psoriasis pill just hit phase 3: a real shot at biologic–level skin clearance

Takeda’s once–daily psoriasis pill just hit phase 3: a real shot at biologic–level skin clearance

New Capabilities
By Newzino Staff |

Zasocitinib’s topline win is now sparking real market and analyst reaction—putting Takeda’s AI-origin TYK2 pill on a faster, higher-stakes path to FY2026 filings and category-defining head-to-head data.

December 19th, 2025: Takeda shares pop after Phase 3 win, signaling investor belief in blockbuster path

Overview

Psoriasis has been an injectable kingdom for years: shots that work great, pills that usually don’t. Takeda’s once-daily TYK2 pill zasocitinib just cleared pivotal Phase 3 topline hurdles—and by the next session investors responded, sending Takeda shares up as much as 4.3% in early Tokyo trading (a seven-month-high intraday jump).

The story is now shifting from “can it work?” to “how big can it get?” Beyond competing with Sotyktu and Otezla in skin, Bloomberg-reported analyst models are explicitly tying peak potential to expansion into larger immune indications like inflammatory bowel disease, while Nimbus’s CEO highlighted how AI sped candidate identification—making upcoming full-data disclosures and FY2026 regulatory submissions the next credibility tests for both the molecule and the AI-enabled origin story.

Key Indicators

>50%
PASI 90 at week 16
More than half reached clear/almost clear skin in Phase 3.
~30%
PASI 100 at week 16
Roughly three in ten achieved completely clear skin in Phase 3.
44
Ranked secondary endpoints met
Takeda says zasocitinib cleared every ranked secondary endpoint, including vs apremilast.
1,801
Patients in two pivotal Phase 3 trials
Latitude trials enrolled 693 and 1,108 participants across 21 countries.
$3B–$6B
Takeda’s stated peak annual sales target
Takeda and analysts frame zasocitinib as a potential blockbuster if approved.
4.3%
Intraday share jump after Phase 3 news
Bloomberg reported Takeda rose as much as 4.3% in early Tokyo trading on Dec. 19 following the topline readout.

Interactive

Exploring all sides of a story is often best achieved with Play.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Sign Up

Debate Arena

Two rounds, two personas, one winner. You set the crossfire.

People Involved

Christophe Weber
Christophe Weber
President and CEO, Takeda (Publicly positioning zasocitinib as a future growth pillar)
Andy Plump
Andy Plump
President of R&D, Takeda (Leading regulatory push and broader immunology expansion strategy)
Michael Nedelcovych
Michael Nedelcovych
Analyst, TD Cowen (Positive on data; cautious on overall oral psoriasis market sizing)
April W. Armstrong
April W. Armstrong
Dermatology clinical investigator and academic dermatologist (Published/investigator on TYK2 oral trial programs)
Jeb Keiper
Jeb Keiper
President and CEO, Nimbus Therapeutics (Positioning Nimbus’s AI/computational approach as a real contributor to zasocitinib’s speed from design to late-stage success)
Stephen Barker
Stephen Barker
Analyst, Jefferies Japan (Framing upside as meaningfully larger if zasocitinib expands beyond psoriasis into broader immune indications)

Organizations Involved

Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
Biopharmaceutical Company
Status: Sponsor and owner of zasocitinib; preparing FDA filings and broader immunology expansion

A global drugmaker betting that zasocitinib can be its next major immunology growth driver.

Nimbus Therapeutics
Nimbus Therapeutics
Biotechnology Company
Status: Originator of the molecule; sold the TYK2 program to Takeda

The computationally driven biotech that created the compound Takeda is now pushing toward approval.

U.S. Food and Drug Administration (FDA)
U.S. Food and Drug Administration (FDA)
Federal Agency
Status: Future regulator for zasocitinib’s NDA; the main gatekeeper for U.S. commercialization

The regulator that will decide whether Phase 3 results translate into an approved once-daily psoriasis pill.

Bristol Myers Squibb
Bristol Myers Squibb
Pharmaceutical Company
Status: Incumbent oral TYK2 competitor via Sotyktu; a key benchmark for Takeda

Maker of Sotyktu, the first approved oral TYK2 inhibitor and Takeda’s most direct comparator.

Timeline

  1. Takeda shares pop after Phase 3 win, signaling investor belief in blockbuster path

    Market

    Bloomberg reported Takeda shares rose as much as 4.3% in early Tokyo trading—the biggest intraday gain in seven months—after the company’s Phase 3 zasocitinib update.

  2. Takeda drops Phase 3 topline win for zasocitinib

    Clinical

    Takeda said two pivotal Latitude Phase 3 trials met co-primary endpoints (sPGA 0/1 and PASI 75) and all ranked secondary endpoints, with more than half reaching PASI 90 and ~30% reaching PASI 100 at week 16.

  3. Pricing pressure arrives: Sotyktu discount move

    Market

    BMS announced a steep direct-to-patient discount for Sotyktu, a signal that access and pricing will shape oral adoption.

  4. Competition heats up: J&J touts an oral challenger

    Competitive

    Reuters reported J&J’s experimental oral psoriasis drug beat Sotyktu in late-stage head-to-head trials, sharpening the oral arms race.

  5. Head-to-head trial starts: Takeda vs Sotyktu

    Clinical

    A Phase 3 study comparing zasocitinib directly with deucravacitinib began, setting up the clearest “winner” evidence.

  6. Takeda expands the bet into psoriatic arthritis (Phase 3)

    Clinical

    Takeda’s Phase 3 psoriatic arthritis program for zasocitinib moved forward, widening the commercial upside beyond skin.

  7. Phase 2b data gets its spotlight at AAD

    Clinical

    Takeda highlighted Phase 2b results showing strong PASI responses at higher doses, signaling “biologic-level” ambition for an oral drug.

  8. Deal closes; Phase 3 becomes Takeda’s problem

    Deal

    Takeda completed the Nimbus TYK2 acquisition, taking full control of TAK-279’s Phase 3 execution and global strategy.

  9. Takeda buys the molecule (and the narrative)

    Deal

    Takeda announced it would acquire Nimbus’s TYK2 program for $4B upfront plus sales milestones, renaming the asset TAK-279.

  10. Nimbus posts the signal that starts the bidding

    Clinical

    Nimbus reported positive Phase 2b topline results for its allosteric TYK2 inhibitor NDI-034858 in plaque psoriasis, setting up a major takeout.

  11. FDA blesses TYK2 as a new oral psoriasis lane

    Regulatory

    FDA approved BMS’s Sotyktu (deucravacitinib), establishing TYK2 inhibition as a viable oral path in plaque psoriasis.

Scenarios

1

FDA Approval in 2027: Takeda Launches a “Biologic-Like” Oral Psoriasis Pill

Discussed by: Takeda (NDA timing guidance) and Reuters/TD Cowen commentary on best-case efficacy positioning

Takeda files its NDA during its fiscal year 2026 (Apr. 1, 2026 to Mar. 31, 2027) and the FDA grants approval on a conventional review cycle. The launch leans on the simplest pitch in dermatology—clear skin without injections—while payers negotiate aggressively because the market is already crowded with powerful biologics. A clean label (especially around safety and labs) becomes the unlock for broad primary-care-to-derm comfort and for meaningful switching from injectables in needle-averse patients.

2

Regulatory Speed Bump: FDA Asks for More Safety or Monitoring Clarity

Discussed by: FDA’s broader safety posture toward immunology pills (post–JAK boxed warnings) and investor caution reflected in analyst commentary

Even with strong efficacy, the FDA slows momentum by pressing Takeda on longer-term safety, rare-event risk management, or monitoring expectations—especially because oral immune modulators have a bruised recent history. The drug still advances, but timelines stretch and commercial messaging shifts from “revolution” to “responsible rollout,” with heavy emphasis on selectivity, real-world pharmacovigilance, and clearer guidance on infections and lab trends.

3

The Oral Category Fragment: Head-to-Head Data Creates Winners and Casualties

Discussed by: Market reporting and competitive readouts highlighted by Reuters, including multiple oral contenders pursuing superiority claims

As head-to-head studies read out (including Takeda’s trial vs deucravacitinib), the market stops treating “oral” as one bucket. A small number of pills earn premium positioning on superiority and durability, while others get boxed into step-therapy niches or price-led access plays. In this world, Takeda’s Phase 3 topline win is necessary but not sufficient—the decisive moment is whether direct comparisons show it is meaningfully better than the incumbent TYK2 standard.

Historical Context

JAK Inhibitors Get a Regulatory Reckoning (Boxed Warnings Expansion)

2019-02 to 2021-09

What Happened

A large safety trial and subsequent FDA reviews linked certain JAK inhibitors to higher risks of serious cardiovascular events, cancers, blood clots, and death. FDA required boxed-warning revisions and narrowed the comfort zone for oral immune pathway drugs.

Outcome

Short Term

Prescribing tightened and risk messaging became central to oral immunology launches.

Long Term

“Safety optics” became a gating factor for any new oral immune modulator, including TYK2s.

Why It's Relevant Today

It explains why Takeda’s story is as much about safety/selectivity as headline clearance rates.

Sotyktu Makes TYK2 Real: The First Approved Oral Allosteric TYK2 Inhibitor

2022-09

What Happened

FDA approved deucravacitinib, validating TYK2’s allosteric approach and proving an oral pill could compete in moderate-to-severe plaque psoriasis. The approval created a clear benchmark—week-16 and week-24 clearance—against which every next entrant would be judged.

Outcome

Short Term

TYK2 became one of the hottest oral immunology mechanisms in dermatology.

Long Term

Competition shifted from “can TYK2 work?” to “whose TYK2 is best, safest, and most reimbursable?”

Why It's Relevant Today

Takeda’s Phase 3 readout is compelling largely because it appears to raise the TYK2 performance bar.

Otezla Opens the Modern Oral Era in Psoriatic Disease

2014

What Happened

FDA approved apremilast (Otezla) first for psoriatic arthritis, then expanded use in plaque psoriasis the same year. It became a widely used oral option by offering convenience and a familiar safety profile, even though efficacy was generally below top biologics.

Outcome

Short Term

Oral systemic therapy became a mainstream patient preference in psoriatic disease.

Long Term

The market learned that convenience can win—if efficacy is “good enough.”

Why It's Relevant Today

It’s the direct backdrop for why a biologic-like oral pill could reshape patient choice and payer strategies.

14 Sources:
+8
Takeda Reuters Nimbus Therapeutics JAMA Dermatology (via PubMed) U.S. Food and Drug Administration FDAAA TrialsTracker LiveMint (via Bloomberg) The Japan Times (via Bloomberg) Takeda Takeda Takeda U.S. Food and Drug Administration Reuters Reuters